The DOI matches its Crossref record.
Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.
Open accessAbstract
Neutrophil (PMN) activation is critical in inflammation and reperfusion injury, suggesting that PMN-directed therapies may be of clinical use. Here, leukotriene B4 (LTB4)-induced PMN influx in ear skin was equivalent between 5-lipoxygenase knockout and wild-type mice. To explore actions of lipoxin (LX) in PMN-mediated tissue injury, we prepared several novel LX stable analogues, including analogues of LXA4 and aspirin-triggered 15-epi-LXA4 as well as LXB4, and examined their impact in PMN infiltration and vascular permeability. Each applied topically to mouse ears inhibited dramatically PMN-mediated increases in vascular permeability (IC50 range of 13-26 nmol) with a rank order of 15(R/S)-methyl-LXA4 > 16-para-fluoro-phenoxy-LXA4 approximately 5(S)-methyl-LXB4 >/= 16-phenoxy-LXA4 > 5(R)-methyl-LXB4. These LX mimetics were as potent as an LTB4 receptor antagonist, yet results from microphysiometry with mouse leukocytes indicated that they do not act as LTB4 receptor level antagonists. In addition, within 24 h of delivery, > 90% were cleared from ear biopsies. Neither IL-8, FMLP, C5a, LTD4, nor platelet-activating factor act topically to promote PMN influx. When applied with LTB4, PGE2 enhanced sharply both infiltration and vascular permeability, which were inhibited by a fluorinated stable analogue of aspirin-triggered LX. These results indicate that mimetics of LXs and aspirin-triggered 15-epi-LXA4 are topically active in this model and are potent inhibitors of both PMN infiltration and PMN-mediated vascular injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Self-citationResolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
Self-citationResolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Self-citationResolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344
“Lipoxins biosynthesized from arachidonic acid are potent, active stop signals for PMN infiltration (9, 10) and are produced during resolution of self-limited inflammatory responses (11, 12).”
BackgroundSelf-citationSerhan, C. N. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141647 · Cited by 997
Self-citationResolvins and protectins in inflammation resolution
Serhan, C. N., & Petasis, N. A. (2011) · Chemical Reviews · doi:10.1021/cr100396c · Cited by 996
Self-citationProresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation
Buckley, C. D., Gilroy, D. W., & Serhan, C. N. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.009 · Cited by 807
Self-citationYe, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C. N., & Murphy, P. M. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001578 · Cited by 764
Self-citationResolvin D2 is a potent regulator of leukocytes and controls microbial sepsis
Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., & Serhan, C. N. (2009) · Nature · doi:10.1038/nature08541 · Cited by 695
Self-citationThe resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
Serhan, C. N., Chiang, N., & Dalli, J. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.004 · Cited by 583
Self-citationLipid Mediators in the Resolution of Inflammation
Serhan, C. N., Chiang, N., Dalli, J., & Levy, B. D. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016311 · Cited by 544
Self-citationResolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases
Van Dyke, T. E., & Serhan, C. N. (2003) · Journal of Dental Research · doi:10.1177/154405910308200202 · Cited by 513
Self-citationAnti-Inflammatory and Proresolving Lipid Mediators
Serhan, C. N., Yacoubian, S., & Yang, R. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151409 · Cited by 507
Self-citationPhysiological roles for ecto-5’-nucleotidase (CD73)
Colgan, S. P., Eltzschig, H. K., Eckle, T., & Thompson, L. F. (2006) · Purinergic Signalling · doi:10.1007/s11302-005-5302-5 · Cited by 500
Specialized pro-resolving lipid mediators in the inflammatory response: An update
Bannenberg, G., & Serhan, C. N. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.08.002 · Cited by 464
The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
Chiang, N., Serhan, C. N., Dahlén, S.-E., Drazen, J. M., Hay, D. W. P., Rovati, G. E., Shimizu, T., Yokomizo, T., & Brink, C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.4 · Cited by 464
Self-citationSerhan, C. N. (2005) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.05.002 · Cited by 454
Self-citationEndogenous pro‐resolving and anti‐inflammatory lipid mediators: a new pharmacologic genus
Serhan, C. N., & Chiang, N. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707489 · Cited by 431
Self-citationSu, S. B., Gong, W., Gao, J.-L., Shen, W., Murphy, P. M., Oppenheim, J. J., & Wang, J. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.395 · Cited by 429
Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation
Serhan, C. N. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100322 · Cited by 421
Self-citationSerhan, C. N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S. P., Stahl, G. L., Merched, A., Petasis, N. A., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6856 · Cited by 404
Self-citationNovel Lipid Mediators Promote Resolution of Acute Inflammation: Impact of Aspirin and Statins
Spite, M., & Serhan, C. N. (2010) · Circulation Research · doi:10.1161/circresaha.110.223883 · Cited by 365
Self-citationResnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., & Blasi, F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022652999 · Cited by 360
Self-citationResolution of inflammation: An organizing principle in biology and medicine
Panigrahy, D., Gilligan, M. M., Serhan, C. N., & Kashfi, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107879 · Cited by 340
Self-citationResolution phase lipid mediators of inflammation: agonists of resolution
Serhan, C. N., & Chiang, N. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.012 · Cited by 331
Self-citationGronert, K., Maheshwari, N., Khan, N., Hassan, I. R., Dunn, M., & Laniado Schwartzman, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410638200 · Cited by 310
Self-citationResolution of Acute Inflammation in the Lung
Levy, B. D., & Serhan, C. N. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170408 · Cited by 298
Self-citationResolvins and protectins: mediating solutions to inflammation
Kohli, P., & Levy, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00290.x · Cited by 292
Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., & Serhan, C. N. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42545 · Cited by 290
Self-citationTargeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287
International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
Brink, C., Dahlén, S.-E., Drazen, J., Evans, J. F., Hay, D. W. P., Nicosia, S., Serhan, C. N., Shimizu, T., & Yokomizo, T. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.8 · Cited by 286
Self-citationNovel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors
N. Serhan, C., Krishnamoorthy, S., Recchiuti, A., & Chiang, N. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611109060629 · Cited by 276
Mas, E., Croft, K. D., Zahra, P., Barden, A., & Mori, T. A. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.190199 · Cited by 270
The Management of Inflammation in Periodontal Disease
Van Dyke, T. E. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080173 · Cited by 261
Dalli, J., & Serhan, C. N. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14336 · Cited by 138
Self-citationA role for lipoxin A4 as an anti-inflammatory mediator in the human endometrium
Macdonald, L. J., Boddy, S. C., Denison, F. C., Sales, K. J., & Jabbour, H. N. (2011) · Reproduction · doi:10.1530/rep-11-0021 · Cited by 65
“The lipoxins act as anti-inflammatory mediators by inhibiting neutrophil infiltration (Takano et al. 1997, 1998, Hachicha et al. 1999) and transmigration (Colgan et al. 1993, Kucharzik et al. 2003) at sites of inflammation, in part via the induction of nitric oxide production to suppress…”
BackgroundChiang, N., & Serhan, C. N. (2006) · Comprehensive Therapy · doi:10.1007/s12019-006-0005-6 · Cited by 17
Self-citationThe lipid paradox in neuroprogressive disorders: Causes and consequences
Morris, G., Berk, M., Walder, K., O’Neil, A., Maes, M., & Puri, B. K. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.017 · Cited by 17
Metadata
- Authors
- Takano, T., Clish, C. B., Gronert, K., Petasis, N., & Serhan, C. N.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-15
- Volume
- 101
- Issue
- 4
- Pages
- 819-826
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2079341705
- Cited by
- 230
- References
- 0
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.